Theravance Biopharma (TBPH) Tops Q1 EPS by 4c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.22), $0.04 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.43 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance